# Beijing Suncadia Pharmaceuticals Co., Ltd: Phase 2 study started recruiting, 340 planned (Acute Ischemic Stroke)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Beijing Suncadia Pharmaceuticals Co., Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients |
| NCT ID | NCT07739160 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Acute Ischemic Stroke |
| Intervention types | drug |
| Target enrollment | 340 |
| Site countries | China |
| Posted | 2026-07-31 |
| Planned start | 2026-09-29 |
| Event | Started recruiting |
| Event date | 2026-09-29 |
| Last update posted | 2026-11-05 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 340 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07739160). Last refreshed: 2026-11-06T09:49:51.899Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.